TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. In the last episode, Dr. Sullivan and Amy Gallant Sullivan discuss the next workshop […]

Dr. Schachter speaks with Azura Ophthalmics CEO Marc Gleeson about the company’s pipeline, which is focused on the development of ophthalmic keratolytics for the treatment of disorders affecting the lid margin and ocular surface. The novel approach targets hyperkeratinization and impaired lipid secretory function of […]

TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. In this penultimate episode of the series, Dr. Sullivan and Amy Gallant Sullivan provide […]

TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. In the diagnostic methodology episode, Dr. Wolffsohn explains the complexities involved in selecting specific […]

TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. In part 2 of the pain and sensation episode, Drs Galor and Hamrah talk […]

TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. In part 1 of this two part episode on pain and sensation, Drs. Galor […]

Dr. Markouli explains that the goal of the pathophysiology committee was first, to understand the normal, healthy, ocular surface and adnexa before discussing the changes that occur in dry eye disease. A key point to come out of the pathophysiology workshop, she notes, is that […]

Robert S. Herrick, MD, a corneal external disease specialist, cofounded Lacrimedics in 1983 and has developed many innovative products and procedures for dry eye disease. In this Industry Spotlight he discusses his journey to a greater understanding of lacrimal system dysfunction, the benefits of occlusion therapy, and the development of […]

TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: https://ocularsurfaceacademy.com. Drs Jones and Deng talk about the importance of clinical evidence to drive proper […]

Glen Curran, Vice President, Marketing, US Eyecare at Allergan discusses the merger with Abbvie and what it was like to go through the transition during the pandemic. He notes how smooth the process was and what Abbvie brings to the table: a focus on science […]